Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.59 |
| ▸ | S1PR4 | O95977 | 1/20 | 0.56 |
| ▸ | S1PR1 | P21453 | 1/20 | 0.56 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.56 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | PLA2G4B | P0C869 | 1/20 | 0.55 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10853292 | 0.98 | LMNA (0.60) | LMNAL3MBTL1ALDH1A1S1PR4S1PR1 | |
| SCHEMBL17345290 | 0.98 | LMNA (0.60) | LMNAL3MBTL1ALDH1A1S1PR4S1PR1 | |
| SCHEMBL26455103 | 0.97 | LMNA (0.66) | LMNAL3MBTL1ALDH1A1FFAR1 | |
| SCHEMBL14951699 | 0.90 | L3MBTL1 (0.76) | LMNAL3MBTL1ALDH1A1TP53FFAR1 | |
| SCHEMBL24723561 | 0.87 | L3MBTL1 (0.82) | LMNAL3MBTL1S1PR4S1PR1S1PR3 | |
| SCHEMBL28035324 | 0.87 | PLA2G4B (0.65) | LMNAL3MBTL1ALDH1A1S1PR4S1PR1 | |
| SCHEMBL8378949 | 0.86 | LMNA (0.79) | LMNAL3MBTL1S1PR4S1PR1S1PR3 | |
| SCHEMBL3488457 | 0.86 | LMNA (0.79) | LMNAL3MBTL1S1PR4S1PR1S1PR3 | |
| SCHEMBL8558255 | 0.86 | LMNA (0.79) | LMNAL3MBTL1S1PR4S1PR1S1PR3 | |
| SCHEMBL2185137 | 0.86 | LMNA (0.79) | LMNAL3MBTL1S1PR4S1PR1S1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | VICTORIA LINK LIMITED (NZ) | 2023-05-04 | — | — | US | disclosed |
| US-5135955-A | Anticoagulants or antifungal activity | ELI LILLY AND COMPANY (US) | 1992-08-04 | — | — | US | disclosed |
| CN-1037330-A | PROPANAMINE DERIVATIVES | LILLY CO ELI (US) | 1989-11-22 | — | — | CN | disclosed |
| EP-0339878-A2 | Propanamine derivatives | ELI LILLY AND COMPANY (US) | 1989-11-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230139366-A1 | BRARTEMICIN ANALOGUES | RXFP1, RXFP2, RXFP4 | LMNA 3705/4885L3MBTL1 4715/4885ALDH1A1 4796/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.